I’m Sudhama Swamy, Director of Strategic Partnerships & Business Development. Thank you for taking a few minutes to hear from me. This message is especially relevant if you’re:

• A pharmaceutical company developing therapies for neuropsychiatric conditions such as PTSD, traumatic brain injury (TBI), depression (including postpartum depression), or anxiety.
• An investor focused on accelerating drug development, optimizing clinical trial design, and prioritizing objective, measurable endpoints.
• An academic research partner exploring the biological underpinnings of psychiatric and mental health disorders.

Who We Are
Polaris Genomics is a precision mental health company at the forefront of integrating next-generation sequencing (NGS) and machine learning to bring biological clarity and objectivity to the diagnosis and treatment of complex mental health and neuropsychiatric conditions.

Our mission is clear: to redefine how mental health is understood and treated — with the same scientific rigor and biomarker-based precision that revolutionized oncology.

What We Offer
Our flagship platform, ADAPT, is a unique transcriptomic tool that captures over 1,000 biomarkers associated with known neuropsychiatric pathways. This tool:

• Accelerates clinical trials by enriching patient selection, reducing time and cost
• Creates objective measures of response to treatment and endpoints

ADAPT™ empowers researchers to:

• Identify novel therapeutic targets that may be missed by traditional techniques
• Objectively monitor the effects of treatment with biomarkers
• Develop diagnostic and therapeutic tools using gene expression data derived from blood samples

In short, it’s time to ADAPT — and redefine the future of mental health R&D.Why Polaris is Different
Our team brings a rare and deeply personal perspective to mental health: our founders are former military leaders with more than 60 years of combined service across the Army, Air Force, and VA. Each of their lived experiences informs our unwavering commitment to tackle some of the most urgent mental health challenges — with science, empathy, and purpose.

We are working toward a future where mental health care is:

• Biologically informed
• Personalized
• And, we are replacing stigma and suffering in silence with science. 

We invite you to reach out — whether you’re a pharma innovator, investor, or researcher — to explore how we can support your goals and work together to shape the future of mental health.

Let’s have a conversation. Let’s chart a new course for mental and brain health care together.